4 withdrawn. 4 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Hypertrophy: new trials by email Literature Review of Hypertrophy trials Research Report on Hypertrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-lesional ACE Inhibitor for Treatment of Hypertrophic Scars Intralesional enalaprilat injection - Hypertrophic Scar | Phase 2 / Phase 3 | Withdrawn | Nova Scotia Health Authority | 2024-08-01 | 2025-02-17 | |
| Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy CDR132L, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 | Withdrawn | Cardior Pharmaceuticals GmbH | 2024-04-30 | 2026-07-07 | |
| Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Valsartan, Placebo Oral Tablet - Aortic Valve Stenosis, Valsartan | Phase 2 / Phase 3 | Withdrawn | University Hospital, Limoges | 2023-01-02 | 2023-03-17 | |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy MEK162 - Cardiomegaly | Phase 2 | Withdrawn | Array Biopharma, now a wholly owned subsidiary of Pfizer | 2012-02-01 | 2020-10-06 |
Cardiomegaly (2) · Aortic Valve Stenosis (1) · Cardiomyopathy, Hypertrophic (1) · Cicatrix (1) · Cicatrix, Hypertrophic (1) · Heart Failure (1) · Hypertrophy, Left Ventricular (1) · Keloid (1) · Noonan Syndrome (1)
Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4) · Cardiovascular Diseases (3) · Heart Diseases (3) · Aortic Valve Disease (2) · Connective Tissue Diseases (2) · Heart Valve Diseases (2) · Skin and Connective Tissue Diseases (2) · Aortic Stenosis, Subvalvular (1) · Aortic Valve Stenosis (1) · Cardiomegaly (1) · Cardiomyopathies (1) · Cardiovascular Abnormalities (1) · Collagen Diseases (1)
Enalaprilat (1) · Valsartan (1) · binimetinib (1)
Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Cardior Pharmaceuticals GmbH (1) · Nova Scotia Health Authority (1) · University Hospital, Limoges (1)
France (1) · United Kingdom (1) · United States (1)
PMID 15253184, PMID 16079683, PMID 19621835, PMID 30087573, PMID 31385893, PMID 7917152